Results 181 to 190 of about 4,378 (208)

Larotrectinib bei TRK-Fusionstumoren

Onkologische Welt, 2019
Wirkstoff Larotrectinib hat im September 2019 eine EU-Zulassung zur Behandlung von erwachsenen und pädiatrischen Patienten mit TRK-Fusionstumoren erhalten. Der orale Wirkstoff ist der erste Vertreter einer neuen Arzneimittelklasse, der gezielt den onkogenen Treiber eines Tumors inhibiert.
openaire   +1 more source

Larotrectinib

Reactions Weekly, 2022
openaire   +1 more source

Larotrectinib-associated withdrawal symptoms resolved following initiation of GLP-1 receptor agonist: a case report

Cancer Chemotherapy and Pharmacology
Reema Patel, J. Deeken
semanticscholar   +1 more source

Larotrectinib/selitrectinib

Reactions Weekly, 2021
openaire   +1 more source

Larotrectinib/lenvatinib

Reactions Weekly, 2022
openaire   +1 more source

Larotrectinib

Reactions Weekly, 2019
openaire   +1 more source

Larotrectinib/temozolomide/vinblastine

Reactions Weekly, 2022
openaire   +1 more source

Crizotinib/larotrectinib/selitrectinib

Reactions Weekly, 2021
openaire   +1 more source

A novel NiCaAl-LDH@ND-COOH nanocomposite-modified electrode for highly sensitive and selective electrochemical detection of larotrectinib in pharmaceutical and biological samples

Microchimica Acta
Elif Naz Öven, Asena Ayşe Genç, N. Erk, Hassanali Ahmed, Mustafa Soylak   +4 more
semanticscholar   +1 more source

LC-MS/MS method development and validation for novel targeted anticancer therapies adagrasib, capmatinib, ensartinib, entrectinib, larotrectinib, lorlatinib, pralsetinib, selpercatinib and sotorasib.

Journal of Pharmaceutical and Biomedical Analysis
M. Meertens, L. Daniëlle de Jong, N. D. Vries, Hilde Rosing, Jos H. Beijnen, A. D. Huitema   +5 more
semanticscholar   +1 more source